IMpower133: patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
Authors
Califano, RaffaeleKazarnowicz, A
Karaseva, N
Sanchez, A
Liu, V
Horn, L
Quach, C
Yu, W
Kabbinavar, F
Lam, S
Mansfield, A
Affiliation
King's College, London, London, United KingdomIssue Date
2018
Metadata
Show full item recordCitation
Califano R, Ka?arnowicz A, Karaseva N, Sánchez A, Liu SV, Horn L, et al. IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Ann Oncol. 2018;29(suppl_10):17.Journal
Annals of OncologyDOI
10.1093/anonc/mdy486Additional Links
https://dx.doi.org/10.1093/anonc/mdy486Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/anonc/mdy486